ALX Oncology (ALXO) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 4 Phase 2[2], 1 Phase 1[3].
Trial NCT05002127[5] evaluates Evorpacept (ALX148) in Gastric Cancer with a target enrollment of 127 participants.
ALXO has 2 Form 4 insider filings recorded at the SEC in the past 30 days[6].